• 1
    McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J.1998; 19(Suppl P): 916.
  • 2
    Lehrke S, Mazhari R, Durand DJ, Zheng M, Bedja D, Zimmet JM, Schuleri KH, Chi AS, Gabrielson KL, Hare JM. Aging impairs the beneficial effect of granulocyte colony-stimulating factor and stem cell factor on post-myocardial infarction remodeling. Circ Res.2006; 99: 553560.
  • 3
    Srinivas G, Anversa P, Frishman WH. Cytokines and myocardial regeneration: a novel treatment option for acute myocardial infarction. Cardiol Rev.2009; 17: 19.
  • 4
    Kanashiro-Takeuchi RM, Tziomalos K, Takeuchi LM, Treuer AV, Lamirault G, Dulce R, Hurtado M, Song Y, Block NL, Rick F, et al. Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci U S A.2010; 107: 26042609.
  • 5
    Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev.1992; 72: 449489.
  • 6
    Belayev L, Khoutorova L, Zhao KL, Davidoff AW, Moore AF, Cramer SC. A novel neurotrophic therapeutic strategy for experimental stroke. Brain Res.2009; 1280: 117123.
  • 7
    Wald MR, Borda ES, Sterin-Borda L. Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: signal transduction pathways. J Cell Physiol.1996; 167: 461468.
  • 8
    Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood.2003; 102: 13401346.
  • 9
    Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res.2002; 64: 326333.
  • 10
    Van Der MP, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. Erythropoietin in cardiovascular diseases. Eur Heart J.2004; 25: 285291.
  • 11
    Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A.2001; 98: 40444049.
  • 12
    Bellone G, Rollino C, Borsa S, Ferrero I, Martina G, Carbone A, Mareschi K, Quarello F, Piccoli G, Emanuelli G, et al. Association between elevated prolactin levels and circulating erythroid precursors in dialyzed patients. Proc Soc Exp Biol Med.2000; 223: 367371.
  • 13
    Bazan JF. A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. Biochem Biophys Res Commun.1989; 164: 788795.
  • 14
    Bellone G, Geuna M, Carbone A, Silvestri S, Foa R, Emanuelli G, Matera L. Regulatory action of prolactin on the in vitro growth of CD34+ve human hemopoietic progenitor cells. J Cell Physiol.1995; 163: 221231.
  • 15
    Kolb B, Morshead C, Gonzalez C, Kim M, Gregg C, Shingo T, Weiss S. Growth factor-stimulated generation of new cortical tissue and functional recovery after stroke damage to the motor cortex of rats. J Cereb Blood Flow Metab.2007; 27: 983997.
  • 16
    Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation.1978; 58: 10721083.
  • 17
    McFarland KC, Sprengel R, Phillips HS, Kohler M, Rosemblit N, Nikolics K, Segaloff DL, Seeburg PH. Lutropin-choriogonadotropin receptor: an unusual member of the G protein-coupled receptor family. Science.1989; 245: 494499.
  • 18
    Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr Rev.2002; 23: 141174.
  • 19
    al-Hader AA, Lei ZM, Rao CV. Neurons from fetal rat brains contain functional luteinizing hormone/chorionic gonadotropin receptors. Biol Reprod.1997; 56: 10711076.
  • 20
    Meng XL, Rennert OM, Chan WY. Human chorionic gonadotropin induces neuronal differentiation of PC12 cells through activation of stably expressed lutropin/choriogonadotropin receptor. Endocrinology.2007; 148: 58655873.
  • 21
    Gage FH. Neurogenesis in the adult brain. J Neurosci.2002; 22: 612613.
  • 22
    Patil AA, Nagaraj MP. The effect of human chorionic gonadotropin (HCG) on functional recovery of spinal cord sectioned rats. Acta Neurochir (Wien).1983; 69: 205218.
  • 23
    Patil AA, Filmore K, Hill D. The effect of human chorionic gonadotropin (HCG) on restoration of physiological continuity of the spinal cord. A preliminary report. Int Surg.1990; 75: 5457.
  • 24
    Van Der MP, Lipsic E, Henning RH, Boddeus K, van d V, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol.2005; 46: 125133.
  • 25
    Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A.2003; 100: 1161211617.
  • 26
    Prunier F, Pfister O, Hadri L, Liang L, Del MF, Liao R, Hajjar RJ. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol.2007; 292: H522H529.
  • 27
    Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A.2003; 100: 48024806.
  • 28
    Boucher M, Pesant S, Lei YH, Nanton N, Most P, Eckhart AD, Koch WJ, Gao E. Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis. Clin Transl Sci.2008; 1: 1320.
  • 29
    Hale SL, Sesti C, Kloner RA. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol.2005; 46: 211215.
  • 30
    Lipsic E, Van Der MP, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol.2004; 44: 473479.
  • 31
    Doue T, Ohtsuki K, Ogawa K, Ueda M, Azuma A, Saji H, Strauss HW, Matsubara H. Cardioprotective effects of erythropoietin in rats subjected to ischemia-reperfusion injury: assessment of infarct size with 99mTc-annexin V. J Nucl Med.2008; 49: 16941700.
  • 32
    George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res.2005; 68: 299306.
  • 33
    Li M, Naqvi N, Yahiro E, Liu K, Powell PC, Bradley WE, Martin DI, Graham RM, Dell’Italia LJ, Husain A. c-kit is required for cardiomyocyte terminal differentiation. Circ Res.2008; 102: 677685.
  • 34
    Olivetti G, Ricci R, Beghi C, Guideri G, Anversa P. Response of the border zone to myocardial infarction in rats. Am J Pathol.1986; 125: 476483.
  • 35
    Nishiya D, Omura T, Shimada K, Matsumoto R, Kusuyama T, Enomoto S, Iwao H, Takeuchi K, Yoshikawa J, Yoshiyama M. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci.2006; 101: 3139.
  • 36
    Hirata A, Minamino T, Asanuma H, Fujita M, Wakeno M, Myoishi M, Tsukamoto O, Okada K, Koyama H, Komamura K, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol.2006; 48: 176184.
  • 37
    Mihov D, Bogdanov N, Grenacher B, Gassmann M, Zund G, Bogdanova A, Tavakoli R. Erythropoietin protects from reperfusion-induced myocardial injury by enhancing coronary endothelial nitric oxide production. Eur J Cardiothorac Surg.2009; 35: 839846.
  • 38
    Qin C, Xiao YB, Zhong QJ, Chen L, Wang XF. Anti-inflammatory effect of erythropoietin pretreatment on cardiomyocytes with hypoxia/reoxygenation injury and the possible mechanism. Chin J Traumatol.2008; 11: 352358.
  • 39
    Nishihara M, Miura T, Miki T, Sakamoto J, Tanno M, Kobayashi H, Ikeda Y, Ohori K, Takahashi A, Shimamoto K. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol.2006; 291: H748H755.
  • 40
    Melloni C, Rao SV, Povsic TJ, Melton L, Kim RJ, Kilaru R, Patel MR, Talan M, Ferrucci L, Longo DL, et al. Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J.2010; 160: 795803.
  • 41
    Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke.2009; 40: e647e656.
  • 42
    Socolovsky M, Dusanter-Fourt I, Lodish HF. The prolactin receptor and severely truncated erythropoietin receptors support differentiation of erythroid progenitors. J Biol Chem.1997; 272: 1400914012.
  • 43
    Socolovsky M, Fallon AE, Lodish HF. The prolactin receptor rescues EpoR-/- erythroid progenitors and replaces EpoR in a synergistic interaction with c-kit. Blood.1998; 92: 14911496.
  • 44
    Dusanter-Fourt I, Muller O, Ziemiecki A, Mayeux P, Drucker B, Djiane J, Wilks A, Harpur AG, Fischer S, Gisselbrecht S. Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin-erythropoietin receptor chimera expressed in lymphoid cells. EMBO J.1994; 13: 25832591.
  • 45
    Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol.1995; 13: 369398.
  • 46
    Watowich SS, Wu H, Socolovsky M, Klingmuller U, Constantinescu SN, Lodish HF. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu Rev Cell Dev Biol.1996; 12: 91128.
  • 47
    Argetsinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN, Carter-Su C. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell.1993; 74: 237244.
  • 48
    Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell.1993; 74: 227236.
  • 49
    Mill JG, Zornoff LA, Okoshi MP, Okoshi K, Padovani CR, Sugisaki M, Leite CM, Cicogna AC. The early administration of growth hormone results in deleterious effects on ventricular remodeling after acute myocardial infarction. Arq Bras Cardiol.2005; 84: 115121.
  • 50
    Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science.1991; 254: 821825.
  • 51
    Castillo AI, Tolon RM, Aranda A. Insulin-like growth factor-1 stimulates rat prolactin gene expression by a Ras, ETS and phosphatidylinositol 3-kinase dependent mechanism. Oncogene.1998; 16: 19811991.
  • 52
    Tsarfaty G, Longo DL, Murphy WJ. Human insulin-like growth factor I exerts hematopoietic growth-promoting effects after in vivo administration. Exp Hematol.1994; 22: 12731277.
  • 53
    Tian ZG, Woody MA, Sun R, Welniak LA, Raziuddin A, Funakoshi S, Tsarfaty G, Longo DL, Murphy WJ. Recombinant human growth hormone promotes hematopoietic reconstitution after syngeneic bone marrow transplantation in mice. Stem Cells.1998; 16: 193199.